Vaccine hepatitis B

Trade name:
Hepatitis B Vaccine

International name:
The vaccine for the prevention of hepatitis B (Vaccine hepatitis B)

Group Affiliation:
MIBP vaccine

Description of the active substance (INN):
A vaccine to prevent hepatitis B

Mode of action:
A vaccine to prevent hepatitis B. Forms specific immunity to the virus of hepatitis B. The immunization in 98% creates a specific immunity to the virus of hepatitis B. The mean values of antibody titers were consistent with standard WHO. Antiviral antibodies in the protective titres persist for at least 5 years.

Hepatitis B (specific immunoprophylaxis infection caused by all known subtypes of the virus).

Hypersensitivity (including to the yeast). C care. Pregnancy, lactation (due to risk of infection with hepatitis B), multiple sclerosis.

Side effects:
Rarely - fever, headache, dizziness, weakness, malaise, myalgia, arthritis, nausea, vomiting, transient increase in activity of "liver" enzymes, skin rashes, and very rarely (without an unambiguous connection with vaccination) - polyneuropathy, optic neuritis , facial nerve palsy, exacerbation of multiple sclerosis, Guillain-Barré syndrome, allergic reactions of immediate type. Local reactions: pain, congestion, swelling, compaction.

Dosage and administration:
In / m (adults and older children are introduced in the deltoid region, children under 2 years - in the anterior-lateral surface of the thigh), adults and children from the age of 16 - 1 ml (20 mg surface antigen of hepatitis B), newborn and child 15 years - 0.5 ml (10 mg surface antigen of hepatitis B virus). It is recommended that the following immunization scheme: 1 dose - in the selected date, 2 dose - after 1 month and 3 dose - 6 months after administration of 1 dose. Revaccination - 1 dose every 5 years. For high-risk groups (newborns whose mothers are infected with hepatitis B; patients, those who visit the regions with a high incidence of hepatitis B): 1 dose - for the current day, 2 and 3 doses - 1 month and 2 months after administration of 1 dose. Revaccination - within 1 year after 3 doses of primary immunization. Before the introduction of a drug should be good stir, since the storage can be formed small quantity of sediment (white with a clear colorless supernate).

In diseases accompanied by fever, vaccinations should be postponed until he recovers. When immunodeficiency and hemodialysis may require the introduction of additional doses of vaccine, because these patients after primary immunization protective antibody titers (> 10 IU / L) could not be induced. Immunization may be ineffective and even harmful in people who are in a latent or progressive stage of hepatitis B. In the conduct of vaccination must be kept in the presence of drugs needed for emergency assistance in the event of an anaphylactic reaction.

The product is compatible with other vaccines. The effect of reducing immunosuppressive therapy.